Contents

#### **Preface XIII**


X Contents


Contents VII

Chapter 19 **Cholesterol and Triglycerides** 

Chapter 21 **Dyslipidemia in Patients with** 

Makoto Goto

Chapter 23 **Predictors of the Common Adverse**

**Drug Reactions of Statins 459**

Romeo-Gabriel Mihăilă

**Emerging Connections 411**  Ajit Vikram and Poduri Ramarao

**Metabolism Disorder in Malignant Hemopathies 391** 

**Lipodystrophy in the Use of Antiretroviral Therapy 427** 

Chapter 20 **Lipids in the Pathogenesis of Benign Prostatic Hyperplasia:** 

Rosana Libonati, Cláudia Dutra, Leonardo Barbosa, Sandro Oliveira, Paulo Lisbôa and Marcus Libonati

Chapter 22 **Fenofibrate: Panacea for Aging-Related Conditions? 447** 

Hadeer Akram AbdulRazzaq, Noorizan Abd Aziz, Yahaya Hassan, Yaman Walid Kassab and Omar Ismail Chapter 19 **Cholesterol and Triglycerides Metabolism Disorder in Malignant Hemopathies 391**  Romeo-Gabriel Mihăilă

VI Contents

Chapter 9 **Pleiotropic Functions of HDL Lead to** 

Chapter 10 **Disrupted VLDL Features and** 

Vassilis Zannis, Andreas Kateifides,

**Protection from Atherosclerosis and Other Diseases 173** 

Panagiotis Fotakis, Eleni Zanni and Dimitris Kardassis

Patricia Aspichueta, Nerea Bartolomé, Xabier Buqué, María José Martínez, Begoña Ochoa and Yolanda Chico

Chapter 11 **Peroxisome Proliferator-Activated Receptor β/δ (PPAR β/δ)** 

**and Regulation of Blood Lipoproteins 263** 

Hossein Fakhrzadeh and Ozra Tabatabaei-Malazy

Fernanda Klein Marcondes, Vander José das Neves, Rafaela Costa, Andrea Sanches, Tatiana Sousa Cunha, Maria José Costa Sampaio Moura, Ana Paula Tanno

**as a Potential Therapeutic Target for Dyslipidemia 215** 

Laia Salvadó, Xavier Palomer and Manuel Vázquez-Carrera

Jana Semakova, Alícia G. Gómez-Valadés and Jose C. Perales

Aisling C. McMahon, Robin Fraser and David G. Le Couteur

**Lipid Ratios as Risk Factors for Cardiovascular Disease 279**

**Lipoprotein Metabolism in Sepsis 199** 

Emma Barroso, Lucía Serrano-Marco,

Chapter 12 **Liver Glucokinase and Lipid Metabolism 235**  Anna Vidal-Alabró, Andrés Méndez-Lucas,

> Dmitri Svistounov, Svetlana N. Zykova, Victoria C. Cogger, Alessandra Warren,

Chapter 15 **Dyslipidemia and Cardiovascular Disease 303**

**Patients with Bipolar I Disorder 321** Asma Ezzaher, Dhouha Haj Mouhamed, Anwar Mechri, Fadoua Neffati, Wahiba Douki, Lotfi Gaha and Mohamed Fadhel Najjar

Chapter 13 **Liver Sinusoidal Endothelial Cells** 

Chapter 14 **Dyslipidemia and Cardiovascular Risk:**

Telmo Pereira

D. Saravane

Chapter 16 **Cardiovascular Risk in Tunisian**

Chapter 17 **Dyslipidemia and Mental Illness 349** 

Chapter 18 **Dyslipidemia Induced by Stress 367** 

and Dulce Elena Casarini


Preface

tissues.

threat.

modalities.

The term dyslipidemia origins from dys- + lipid (fat) + -emia (in the blood), and essentially refers to serum lipid disorders. By definition, dyslipidemia is a disorder of lipoprotein metabolism in terms of either lipoprotein overproduction or deficiency. It may be expressed by increased serum total cholesterol, low-density lipoprotein cholesterol and/or triglycerides, a decrease in high-density lipoprotein cholesterol concentration, and/or various combinations of such disorders. Lipoproteins, which contain lipids and proteins (apolipoproteins), are mainly responsible for transporting plasma lipids from the intestines and liver to peripheral

Dyslipidemia has a complex pathophysiology consisting of various genetic, lifestyle, and environmental factors. It has many adverse health impacts, and has a pivotal role

Significant ethnic differences exist due to the prevalence and types of lipid disorders. While elevated serum total and LDL-cholesterol are the main concern in Western populations, in other countries hypertriglyceridemia and low HDLcholesterol are more prevalent. The latter types of lipid disorders are considered as components of the metabolic syndrome, which is a clustering of dyslipidemia, hypertension, dysglycemia, and obesity. The rapid escalating trend of obesity at global level, which is associated with obesogenic milieus through high-calorie intake and sedentary lifestyle, as well as the environmental factors, will result in increasing prevalence of dyslipidemia, and will make it a global medical and public health

This situation is not limited to adults, and the pediatric age group is being involved more and more. The results of longitudinal studies support the association of risk

However, the processes by which lipids and lipoproteins participate in the development of non-communicable diseases at different life stages continue to be an area of controversy. Several experimental and clinical research studies are being conducted regarding issues related to the underlying mechanisms and therapeutic

factors cluster in children and adolescents with future chronic diseases.

in the development of chronic non-communicable diseases.
